Anika Therapeutics, Inc. Appoints Mira Leiwant as Vice President of Regulatory Affairs, Quality and Clinical Affairs
October 14, 2019 at 08:30 am EDT
Share
Anika Therapeutics, Inc. announced the appointment of Mira Leiwant to the newly created position of Vice President of Regulatory Affairs, Quality and Clinical Affairs. Ms. Leiwant joins the company with over 20 years of experience leading the regulatory, quality, and clinical affairs strategies for companies specializing in developing, manufacturing, and commercializing medical devices and pharmaceutical products. In this role, Ms. Leiwant will oversee Anika’s global regulatory and clinical strategy, regulatory submissions, interactions with U.S. and international governmental health authorities, and quality and clinical affairs teams and processes. Prior to joining Anika, Ms. Leiwant spent three years at BTG International, as Vice President, Regulatory Affairs.
Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
ANIKA THERAPEUTICS, INC. 
